In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spun Out, Covidien Rolls On

Executive Summary

Covidien, nearly a year removed from spinning out of scandal-plagued parent Tyco International, is pushing forward as an independent company. Covidien execs are investing in new product creation, sales and marketing efforts, and acquisitions. That means Covidien is about to make a big splash in the device industry, with devices bringing in two-thirds of this ambitious company's revenues.
Advertisement

Related Content

Covidien Runs Familiar But Different Plays to Build Vascular Franchise
Covidien Set to Compete in Vascular Business
NOTES: Revolutionizing Surgery
Closing the Gap in Ventral Hernia Repair
Tyco Healthcare: Surviving Scandal
Can Tyco Healthcare Go It Alone?
Can Tyco Healthcare Go It Alone?
Tyco Buys Bard, While Medtronic Scoops Up MiniMed
What Makes Tyco Run?
Tyco Takes a Huge Step Forward with US Surgical Acquisition

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel